Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.

Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, Wijnhoven PWG, Follia V, James N, Farrington PM, Karmokar A, Willis SE, Cairns J, Nikkilä J, Beattie D, Lamont GM, Finlay MRV, Wilson J, Smith A, O'Connor LO, Ling S, Fawell SE, O'Connor MJ, Hollingsworth SJ, Dean E, Goldberg FW, Davies BR, Cadogan EB.

Nat Commun. 2019 Nov 7;10(1):5065. doi: 10.1038/s41467-019-12836-9.

2.

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.

Willoughby CE, Jiang Y, Thomas HD, Willmore E, Kyle S, Wittner A, Phillips N, Zhao Y, Tudhope SJ, Prendergast L, Junge G, Madia Lourenco L, Finlay MRV, Turner P, Munck JM, Griffin RJ, Rennison T, Pickles J, Cano C, Newell DR, Reeves HL, Ryan AJ, Wedge SR.

J Clin Invest. 2019 Oct 3. pii: 127483. doi: 10.1172/JCI127483. [Epub ahead of print]

3.

Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.

Finlay MRV, Anderton M, Bailey A, Boyd S, Brookfield J, Cairnduff C, Charles M, Cheasty A, Critchlow SE, Culshaw J, Ekwuru T, Hollingsworth I, Jones N, Leroux F, Littleson M, McCarron H, McKelvie J, Mooney L, Nissink JWM, Perkins D, Powell S, Quesada MJ, Raubo P, Sabin V, Smith J, Smith PD, Stark A, Ting A, Wang P, Wilson Z, Winter-Holt JJ, Wood JM, Wrigley GL, Yu G, Zhang P.

J Med Chem. 2019 Jul 25;62(14):6540-6560. doi: 10.1021/acs.jmedchem.9b00260. Epub 2019 Jul 16.

PMID:
31199640
4.

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.

Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack PC, Cross DAE.

Mol Cancer Ther. 2018 May;17(5):885-896. doi: 10.1158/1535-7163.MCT-17-0758. Epub 2018 Feb 26.

5.

The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M.

Butterworth S, Cross DAE, Finlay MRV, Ward RA, Waring MJ.

Medchemcomm. 2017 May 10;8(5):820-822. doi: 10.1039/c7md90012k. eCollection 2017 May 1.

6.

Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.

Winter JJ, Anderson M, Blades K, Brassington C, Breeze AL, Chresta C, Embrey K, Fairley G, Faulder P, Finlay MR, Kettle JG, Nowak T, Overman R, Patel SJ, Perkins P, Spadola L, Tart J, Tucker JA, Wrigley G.

J Med Chem. 2015 Mar 12;58(5):2265-74. doi: 10.1021/jm501660t. Epub 2015 Feb 26.

7.

Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2.

Pike KG, Morris J, Ruston L, Pass SL, Greenwood R, Williams EJ, Demeritt J, Culshaw JD, Gill K, Pass M, Finlay MR, Good CJ, Roberts CA, Currie GS, Blades K, Eden JM, Pearson SE.

J Med Chem. 2015 Mar 12;58(5):2326-49. doi: 10.1021/jm501778s. Epub 2015 Feb 18.

PMID:
25643210
8.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL.

J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1.

PMID:
25271963
9.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.

10.

Potential strategies for increasing drug-discovery productivity.

Cumming JG, Finlay MR, Giordanetto F, Hemmerling M, Lister T, Sanganee H, Waring MJ.

Future Med Chem. 2014 Apr;6(5):515-27. doi: 10.4155/fmc.14.7.

PMID:
24649955
11.

Righteousness in the land of forgetfulness.

Finlay MR.

J Relig Health. 2015 Feb;54(1):279-86. doi: 10.1007/s10943-013-9813-z.

12.

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).

Ward RA, Anderton MJ, Ashton S, Bethel PA, Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross DA, Dakin LA, Debreczeni JÉ, Eberlein C, Finlay MR, Hill GB, Grist M, Klinowska TC, Lane C, Martin S, Orme JP, Smith P, Wang F, Waring MJ.

J Med Chem. 2013 Sep 12;56(17):7025-48. doi: 10.1021/jm400822z. Epub 2013 Aug 30.

PMID:
23930994
13.

Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.

Finlay MR, Griffin RJ.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5352-9. doi: 10.1016/j.bmcl.2012.06.053. Epub 2012 Jul 1. Review.

14.

Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.

Finlay MR, Buttar D, Critchlow SE, Dishington AP, Fillery SM, Fisher E, Glossop SC, Graham MA, Johnson T, Lamont GM, Mutton S, Perkins P, Pike KG, Slater AM.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4163-8. doi: 10.1016/j.bmcl.2012.04.036. Epub 2012 Apr 13.

PMID:
22607682
15.

DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain.

Clapham KM, Bardos J, Finlay MR, Golding BT, Griffen EJ, Griffin RJ, Hardcastle IR, Menear KA, Ting A, Turner P, Young GL, Cano C.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):966-70. doi: 10.1016/j.bmcl.2010.12.047. Epub 2010 Dec 13.

PMID:
21216595
16.

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.

Jones CD, Andrews DM, Barker AJ, Blades K, Byth KF, Finlay MR, Geh C, Green CP, Johannsen M, Walker M, Weir HM.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9. doi: 10.1016/j.bmcl.2008.10.075. Epub 2008 Oct 22.

PMID:
18986805
17.

Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.

Anderson M, Andrews DM, Barker AJ, Brassington CA, Breed J, Byth KF, Culshaw JD, Finlay MR, Fisher E, McMiken HH, Green CP, Heaton DW, Nash IA, Newcombe NJ, Oakes SE, Pauptit RA, Roberts A, Stanway JJ, Thomas AP, Tucker JA, Walker M, Weir HM.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5487-92. doi: 10.1016/j.bmcl.2008.09.024. Epub 2008 Sep 10.

PMID:
18815031
18.

Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.

Finlay MR, Acton DG, Andrews DM, Barker AJ, Dennis M, Fisher E, Graham MA, Green CP, Heaton DW, Karoutchi G, Loddick SA, Morgentin R, Roberts A, Tucker JA, Weir HM.

Bioorg Med Chem Lett. 2008 Aug 1;18(15):4442-6. doi: 10.1016/j.bmcl.2008.06.027. Epub 2008 Jun 12.

PMID:
18617397
19.

Total synthesis of 16-desmethylepothilone B, epothilone B10, epothilone F, and related side chain modified epothilone B analogues.

Nicolaou KC, Hepworth D, King NP, Finlay MR, Scarpelli R, Pereira MM, Bollbuck B, Bigot A, Werschkun B, Winssinger N.

Chemistry. 2000 Aug 4;6(15):2783-800.

PMID:
10985727
20.

Total synthesis of epothilone E and related side-chain modified analogues via a Stille coupling based strategy.

Nicolaou KC, King NP, Finlay MR, He Y, Roschangar F, Vourloumis D, Vallberg H, Sarabia F, Ninkovic S, Hepworth D.

Bioorg Med Chem. 1999 May;7(5):665-97.

PMID:
10400321
21.

Synthesis and biological properties of C12,13-cyclopropyl-epothilone A and related epothilones.

Nicolaou KC, Finlay MR, Ninkovic S, King NP, He Y, Li T, Sarabia F, Vourloumis D.

Chem Biol. 1998 Jul;5(7):365-72.

22.
23.

Quackery and cookery: Justus von Liebig's extract of meat and the theory of nutrition in the Victorian age.

Finlay MR.

Bull Hist Med. 1992 Fall;66(3):404-18. No abstract available.

PMID:
1392506
24.

The Rehabilitation of an Agricultural Chemist: Justus Von Liebig and the Seventh Edition.

Finlay MR.

Ambix. 1991 Nov 1;38(3):155-167. doi: 10.1179/amb.1991.38.3.155. No abstract available.

PMID:
28967848

Supplemental Content

Loading ...
Support Center